01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines Announces Management Team Appointments
December 02, 2021 07:00 ET | Praxis Precision Medicines, Inc.
BOSTON, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines to Present at Piper Sandler’s 33rd Annual Virtual Healthcare Conference
November 24, 2021 09:00 ET | Praxis Precision Medicines, Inc.
BOSTON, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2021 Financial Results
November 03, 2021 07:00 ET | Praxis Precision Medicines, Inc.
Enrollment on track for 1H22 topline results for PRAX-114 Phase 2/3 monotherapy MDD Aria Study and for PRAX-114 Phase 2 dose-ranging MDD Acapella Study PRAX-114 Phase 2 studies in post-traumatic...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines To Provide Corporate Update And Report Third Quarter 2021 Financial Results On Wednesday, November 3, 2021
October 22, 2021 09:00 ET | Praxis Precision Medicines, Inc.
BOSTON, Oct. 22, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines to Present at Citi’s 16th Annual BioPharma Virtual Conference
September 01, 2021 09:00 ET | Praxis Precision Medicines, Inc.
CAMBRIDGE, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2021 Financial Results
August 16, 2021 08:00 ET | Praxis Precision Medicines, Inc.
Initiated PRAX-114 Phase 2 Acapella Study for adjunctive treatment of Major Depressive Disorder (MDD) Enrollment on track for 1H22 topline results in PRAX-114 Phase 2/3 Aria Study for monotherapy...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines Reports PRAX-114 Perimenopausal Depression (PMD) Phase 2a Proof-of-Concept Trial Results and Announces Plans to Advance to Phase 2b Study in Women with Menopausal and Mood Symptoms
August 16, 2021 07:55 ET | Praxis Precision Medicines, Inc.
PRAX-114 showed rapid and marked improvements in menopausal and mood symptoms in Phase 2a PMD study PRAX-114 was well tolerated in Phase 2a PMD study with no change in overall safety profile ...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines to Present at 2021 Wedbush PacGrow Healthcare Conference
August 02, 2021 09:00 ET | Praxis Precision Medicines, Inc.
CAMBRIDGE, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines to Present at Upcoming Investor Conferences
July 06, 2021 09:00 ET | Praxis Precision Medicines, Inc.
CAMBRIDGE, Mass., July 06, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines Appoints Tim Kelly as Chief Financial Officer
May 25, 2021 08:00 ET | Praxis Precision Medicines, Inc.
CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...